A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children from 2 to Less than 12 Years of Age with Moderate to Severe Atopic Dermatitis (START UP)

  • Lee, Isaac (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date17/10/24 → 16/10/29